Blood Test May Trump Standard for Early Down Syndrome Screening
|
By LabMedica International staff writers Posted on 14 Apr 2015 |
A new multicenter study provides landmark evidence that a blood test undertaken between 10 to 14 weeks of pregnancy may be more accurate in diagnosing Down syndrome (DS), and two less common chromosomal abnormalities, than standard noninvasive screening techniques.
The research team, led by first author Mary Norton, MD, professor of clinical obstetrics and gynecology at University of California San Francisco (UCSF; San Francisco, CA, USA), followed pregnancy outcomes in close to 16,000 women (average age 30, with approximately 25% over 35). The cell-free DNA (cfDNA) blood test resulted in correctly identifying all 38 fetuses with DS, confirmed by newborn exam, prenatal or postnatal genetic analysis. The test focuses on the small percentage of fetal DNA in a pregnant woman’s blood. DNA from the targeted genes is molecularly “photocopied” and amplified by PCR, products are sequenced, and comparisons are made between relative amounts of the chromosomal DNA.
With standard screening, only 30 of the 38 fetuses with DS were identified. The standard screening comprises a blood sample in which hormones and proteins associated with chromosomal defects are identified, together with an ultrasound of the nuchal fold fluid in the back of the neck, an excess of which is suggestive of DS.
A second compelling advantage of cfDNA analysis was the relatively low incidence of DS misdiagnoses. While standard testing is acknowledged to result in a large number of false-positives, these were significantly less likely with the cfDNA test, which resulted in 9 false-positives vs. 854 with standard screening.
While far fewer cases of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) were found in the study population, the accuracy of cfDNA screening still surpassed standard screening.
The researchers emphasized areas of caution. Standard screening “can identify risk for a broad array of abnormalities that are not detectable on cfDNA testing,” they said. Additionally, a surprisingly high number of aneuploidies were present in the 488 pregnant women whose blood samples were disqualified (due to inadequate or immeasurable quantity of fetal DNA, or assay failure, or high sequencing-variance that could lead to misinterpreting results). Had this disqualified cohort been included in the findings, detection rates of the cfDNA test would have been lower.
cfDNA tests will result in far fewer false-positives than current screening, and so can reduce the number of invasive tests and of miscarriages wrongly attributed to positives. However, patients should be made aware of its limitations. “Providers need to be attuned to patients’ preferences and counsel them about the differences in prenatal screening options. Women who opt for cfDNA testing should be informed that it is highly accurate for DS, but it focuses on a small number of chromosomal abnormalities and does not provide the comprehensive assessment available with other approaches,” said Prof. Norton, “Counseling should also include information about the risks associated with failed tests and the pros and cons of pursuing invasive testing if no results are obtained.”
The study, by Norton M et al., was published April 1, 2015, in the New England Journal of Medicine.
Related Links:
University of California San Francisco
Ariosa Diagnostics’s Harmony prenatal blood test for trisomy 21, 18, & 13
Perinatal Quality Foundation
The research team, led by first author Mary Norton, MD, professor of clinical obstetrics and gynecology at University of California San Francisco (UCSF; San Francisco, CA, USA), followed pregnancy outcomes in close to 16,000 women (average age 30, with approximately 25% over 35). The cell-free DNA (cfDNA) blood test resulted in correctly identifying all 38 fetuses with DS, confirmed by newborn exam, prenatal or postnatal genetic analysis. The test focuses on the small percentage of fetal DNA in a pregnant woman’s blood. DNA from the targeted genes is molecularly “photocopied” and amplified by PCR, products are sequenced, and comparisons are made between relative amounts of the chromosomal DNA.
With standard screening, only 30 of the 38 fetuses with DS were identified. The standard screening comprises a blood sample in which hormones and proteins associated with chromosomal defects are identified, together with an ultrasound of the nuchal fold fluid in the back of the neck, an excess of which is suggestive of DS.
A second compelling advantage of cfDNA analysis was the relatively low incidence of DS misdiagnoses. While standard testing is acknowledged to result in a large number of false-positives, these were significantly less likely with the cfDNA test, which resulted in 9 false-positives vs. 854 with standard screening.
While far fewer cases of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) were found in the study population, the accuracy of cfDNA screening still surpassed standard screening.
The researchers emphasized areas of caution. Standard screening “can identify risk for a broad array of abnormalities that are not detectable on cfDNA testing,” they said. Additionally, a surprisingly high number of aneuploidies were present in the 488 pregnant women whose blood samples were disqualified (due to inadequate or immeasurable quantity of fetal DNA, or assay failure, or high sequencing-variance that could lead to misinterpreting results). Had this disqualified cohort been included in the findings, detection rates of the cfDNA test would have been lower.
cfDNA tests will result in far fewer false-positives than current screening, and so can reduce the number of invasive tests and of miscarriages wrongly attributed to positives. However, patients should be made aware of its limitations. “Providers need to be attuned to patients’ preferences and counsel them about the differences in prenatal screening options. Women who opt for cfDNA testing should be informed that it is highly accurate for DS, but it focuses on a small number of chromosomal abnormalities and does not provide the comprehensive assessment available with other approaches,” said Prof. Norton, “Counseling should also include information about the risks associated with failed tests and the pros and cons of pursuing invasive testing if no results are obtained.”
The study, by Norton M et al., was published April 1, 2015, in the New England Journal of Medicine.
Related Links:
University of California San Francisco
Ariosa Diagnostics’s Harmony prenatal blood test for trisomy 21, 18, & 13
Perinatal Quality Foundation
Latest Molecular Diagnostics News
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
- Combined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
- Blood RNA Test May Detect Precursors to Ovarian Cancer
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







